The CAR T Revolution Continues: Progress Against Solid Tumors Post author:andrewkaretas Post published:May 2, 2023 Post category:Perspectives Continue ReadingThe CAR T Revolution Continues: Progress Against Solid Tumors
TRAVERSE: A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 in Patients with Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) Post author:andrewkaretas Post published:April 6, 2023 Post category:CD70/Scientific Publications Continue ReadingTRAVERSE: A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 in Patients with Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Selective Targeting of Host CD70+ Alloreactive Cells With a CD70 Dagger™ Receptor to Prolong Allogeneic CAR T Cell Persistence Post author:andrewkaretas Post published:February 18, 2023 Post category:PLATFORM/Scientific Publications Continue ReadingSelective Targeting of Host CD70+ Alloreactive Cells With a CD70 Dagger™ Receptor to Prolong Allogeneic CAR T Cell Persistence
Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer Post author:andrewkaretas Post published:January 18, 2023 Post category:DLL3/Scientific Publications Continue ReadingAllogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
Allogeneic BCMA-Targeting CAR T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 UNIVERSAL Trial Interim Results Post author:andrewkaretas Post published:January 18, 2023 Post category:BCMA/Scientific Publications Continue ReadingAllogeneic BCMA-Targeting CAR T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 UNIVERSAL Trial Interim Results
Reuniting for the Next Revolution of CAR T Post author:andrewkaretas Post published:January 6, 2023 Post category:Perspectives Continue ReadingReuniting for the Next Revolution of CAR T
Poster, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma Post author:andrewkaretas Post published:December 18, 2022 Post category:BCMA/Scientific Publications Continue ReadingPoster, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Presentation, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma Post author:andrewkaretas Post published:December 7, 2022 Post category:BCMA/Scientific Publications Continue ReadingPresentation, UNIVERSAL Updated Phase 1 Data Highlight Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Generation of Hypoimmunogenic Allogeneic CAR T Cells by Inactivation of Transcriptional Regulators of HLA Class I and II Genes Post author:andrewkaretas Post published:November 18, 2022 Post category:PLATFORM/Scientific Publications Continue ReadingGeneration of Hypoimmunogenic Allogeneic CAR T Cells by Inactivation of Transcriptional Regulators of HLA Class I and II Genes
A First-of-its-Kind Initiative with Leading Oncologists Hopes to Usher in the Allogeneic Cell Therapy Revolution… Post author:andrewkaretas Post published:October 11, 2022 Post category:Perspectives Continue ReadingA First-of-its-Kind Initiative with Leading Oncologists Hopes to Usher in the Allogeneic Cell Therapy Revolution…
